Insights - Merrimack Pharmaceuticals (NASDAQ:MACK) and Baxter (NYSE:BAX) have climbed into bed on MM-398, Merrimack’s drug candidate for the treatment of metastatic pancreatic cancer, in a licensing deal worth … Continue Reading
Read NowInsights - Titan Pharmaceuticals (TTNP) announced on Tuesday that enrollment in a final phase 3 trial of Probuphine has reached the halfway mark, and that the company continues … Continue Reading
Read NowInsights - A phase 3 trial of Threshold Pharma’s (THLD) hypoxia-targeting therapeutic, TH-302, in soft-tissue sarcoma will continue as planned following an interim analysis of the ongoing … Continue Reading
Read NowInsights - Avanir Pharmaceuticals (AVNR) added $400 million to its valuation on Monday morning with positive results from a phase 2 trial evaluating the safety and efficacy of AVP-923 in Alzheimer’s … Continue Reading
Read NowInsights - Hyperion Therapeutics (HPTX) shuttered development of DiaPep277 in newly diagnosed Type 1 diabetes on Monday, citing improper trial conduct from the drug’s original developer, Andromeda Biotech. Hyperion acquired … Continue Reading
Read NowInsights - Infinity Pharmaceuticals (INFI) and AbbVie Inc. (ABBV) have entered into a major partnership to develop and commercialize duvelisib (IPI-145), Infinity’s oral phosphoinositide-3-kinase (PI3K) inhibitor. PI3K inhibitors were the cat’s meow in … Continue Reading
Read NowInsights - Ampio Pharmaceuticals (AMPE) reported results from the botched STEP Study on Tuesday morning, spinning the failed trial of Ampion in osteoarthritis of the knee as positively … Continue Reading
Read Now
